Oxygen Therapy for Retinal Ischemia

Normobaric Nocturnal Hyperoxia Therapy for Treating Ischemic-Related Retinal Conditions

Status

Withdrawn

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03730779

Enrollment

Registered

2018-11-05

Start date

2018-11-30

Completion date

2020-01-01

Last updated

2020-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinal Ischemia

Brief summary

The investigators will be using nocturnal normobaric hyperoxia therapy in patients with diagnoses of conditions related to retinal ischemia.

Detailed description

Patients who receive a diagnosis of a condition relate to retinal ischemia and who pass the eligibility criteria will receive an oxygen concentrator to use at home. They will report back in follow up monthly for three to six months.

Interventions

DRUGHyperoxia

Patients will receive nocturnal normobaric hyperoxia therapy

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diagnosis of retinal-ischemia related condition

Exclusion criteria

* Complicating other ocular condition * History of smoking or lung conditions

Design outcomes

Primary

Measure	Time frame	Description
Best Corrected Visual Acuity	6 months	Best Corrected Visual Acuity as measured by ETDRS chart
Macula Edema	6 months	Amount of ME present, as measured by OCT

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026